Rituximab Maintenance After Autologous Transplantation

Stopped early · Phase 3

Conditions studied: Non-Hodgkin's Lymphoma

In brief

The goal of this clinical research is to see if Rituxan (rituximab) therapy given after high dose chemotherapy and transplant of a patients own stem cells will prevent or delay the return of the lymphoma.

Key facts

Study ID

NCT01103388

Run by

M.D. Anderson Cancer Center

People needed

4

Starts

2003-08-01

Expected to finish

2010-04-01

Last updated by the study team

2012-07-30

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with diffuse large B cell non-Hodgkin's lymphoma who are 5-6 months status post an autologous stem cell transplant and are in CR. Patients who are positive for t(14;18) by PCR or for BCL-2 by Southern blot are eligible provided there is no other disease present.
• Absolute neutrophil count (ANC) > 1500/mm3 independent of growth factor support
• No evidence of symptomatic cardiac or pulmonary disease
• Platelet count > 75,000 mm3
• Zubrod performance status of 2 or less.
• Negative pregnancy test in patients of "child bearing potential"

You may not qualify if…

• Uncontrolled active infection
• Severe concomitant medical or psychiatric illness
• Serum bilirubin > 2.0 mg/dl 4) Transaminases > 2xULN 5) Serum creatinine > 2.0 mg/dl

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.